Articles tagged "Highly-sensitized"

2020 American Transplant Congress
Anti-HLA IgM Antibodies are Unaffected by Imlifidase (IdeS) Treatment
A. Runström¹, R. Bockermann¹, K. Sjöholm¹, K. M. Roupé¹, Å. Schiött¹, L. Winstedt¹, C. Kjellman¹, T. Lorant²
¹Hansa Biopharma AB, Lund, Sweden, ²Section of Transplantation Surgery, Department of Surgical Sciences, Uppsala, Sweden
*Purpose: The immunoglobulin G (IgG)-degrading cysteine protease, imlifidase (IdeS) is an IgG endopeptidase under development as a rapid desensitization treatment in kidney transplantation. Imlifidase is…
2020 American Transplant Congress
Outcomes of Post-Transplant Desensitization in High Immunological Risk Deceased Donor Kidney Transplant Recipients
D. Kumar, C. Song, L. Kamal, I. Moinuddin, M. Levy, C. Bhati, A. King, P. Kimball, G. Gupta
Virginia Commonwealth University, Richmond, VA
*Purpose: The kidney allocation system (KAS) was changed in 2015 to increase access to transplants for highly sensitized patients. However, recent data suggests that even…
2020 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (NCT03380962): 12m Follow-Up
A. A. Vo¹, N. Ammerman¹, E. Huang¹, M. Toyoda², S. Ge², A. Peng¹, R. Najjar¹, S. Williamson¹, C. Meyers¹, S. Sethi¹, K. Lim¹, J. Choi¹, S. C. Jordan¹
¹Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: IL-6 mediates inflammation and activation of T-cells, B-cells & plasma cells. Thus, IL-6 may represent an important target for desensitization (DES). Here we report…
2020 American Transplant Congress
Infectious Complications in Elderly Kidney Transplant Recipients Undergoing Desensitization
S. Sethi, R. Najjar, A. Peng, A. Vo, S. Jordan, E. Huang
Cedars Sinai Medical Center, West Hollywood, CA
*Purpose: Data is limited on the impact of desensitization on infectious complications in elderly kidney transplant (KT) recipients. We examined infectious complications in elderly KT…
2020 American Transplant Congress
Preformed Anti-HLA Donor-Specific Antibodies Immunological Risk Assessment: The Importance of HLA Antibody Locus-Specificity
V. Jucaud¹, A. Babu², D. Briggs³, N. Krishnan⁴, D. Mitchell⁵, M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²University Hospitals Coventry and Warwickshire, Coventry, United Kingdom, ³NHS Blood and Transplant, Birmingham, United Kingdom, ⁴University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ⁵University of Warwick Medical School, Coventry, United Kingdom
*Purpose: The screening of preformed donor-specific HLA antibodies (pfDSA) by single antigen bead assays has increased the complexity of pre-transplant patient risk stratification. We evaluated…
2020 American Transplant Congress
Feasibility and Limitations of Desensitization Therapy in Highly Sensitized Pediatric ESRD Patients: A Single-Center Experience
J. Steggerda¹, H. Pizzo², X. Zhang³, J. Garrison², I. Kim¹, M. Haas⁴, A. Vo¹, S. Jordan¹, D. Puliyanda²
¹Comprehensive Transplant Center, Cedars-Sinai Med Ctr, West Hollywood, CA, ²Pediatric Nephrology, Cedars-Sinai Med Ctr, West Hollywood, CA, ³HLA Laboratory, Cedars-Sinai Med Ctr, West Hollywood, CA, ⁴Renal Pathology, Cedars-Sinai Med Ctr, West Hollywood, CA
*Purpose: There are a growing number of pediatric (peds) patients (pts) awaiting renal transplantation (tx) who are considered highly sensitized (HS). We report long-term outcomes…
2020 American Transplant Congress
Impact of Desensitization Strategies with Proteosome Inhibition and Costimulation Blockade on Xenoreactive Humoral Responses
B. P. Lovasik¹, A. J. Matar¹, D. A. Faber¹, D. V. Mathews¹, C. P. Breeden¹, S. C. Kim¹, A. J. Tector², A. B. Adams¹
¹Emory University School of Medicine, Atlanta, GA, ²University of Miami, Miami, FL
*Purpose: “Delayed” antibody-mediated xenograft rejection is the one of the most important obstacles to clinical application of pig organ xenografts. The aim of this study…
2020 American Transplant Congress
Risk Stratification in Antibody Incompatible Kidney Transplantation: Can Aggressive Rejection be Avoided?
S. Punjala¹, M. Ibrahim¹, N. Vallant¹, N. Kessaris¹, O. Shaw², N. Mamode¹
¹Department of Nephrology, Renal Transplant and Urology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom, ²Clinical Transplantation Laboratory, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
*Purpose: Our experience in antibody incompatible kidney transplantation, and anecdotal reports, suggest that a specific form of rejection, which we term Early Aggressive Antibody Mediated…
2020 American Transplant Congress
Clazakizumab (Anti-IL-6 Monoclonal) as an Agent to Reduce Donor Specific Hla Antibodies (DSA) and Improve Outcomes in Patients with Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation (NCT03380377)
S. C. Jordan, N. Ammerman, M. Toyoda, S. Ge, E. Huang, A. Peng, S. Sethi, R. Najjar, E. Ortiz, M. Chu, A. De Guzman, I. Kim, K. Lim, J. Choi, A. Vo
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Highly sensitized (HS) patients are at an increased risk for chronic antibody mediated rejection (cABMR) and graft loss due to persistent, deleterious DSA production.…
2020 American Transplant Congress
Assessment of Infectious Complications Following ABO-Blood Group Incompatible Renal Transplant
J. Banbury¹, T. Loosier¹, C. Lin², K. Gutierrez¹
¹University of Alabama at Birmingham Hospital, Birmingham, AL, ²Center for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, AL
*Purpose: In response to the ongoing organ shortage, ABO-incompatible (ABOi) renal transplant (RT) provides an alternative option for patients with end-stage kidney disease. Literature suggests…